The Journal of Urology
Volume 178, Issue 3, Supplement , Pages S42-S48 , September 2007

Bone Directed Therapies for Prostate Cancer

  • Deborah A. Bradley

      Affiliations

    • Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan
    • ,
  • Maha Hussain

      Affiliations

    • Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan
    • Corresponding Author InformationCorrespondence: 7314 CCGC, 1500 East Medical Center Dr., University of Michigan Medical Center, Ann Arbor, Michigan 48109-0946 (telephone: 734-936-8906; FAX: 734-615-2719).
    • ,
  • Robert S. DiPaola

      Affiliations

    • Cancer Institute of New Jersey, New Brunswick, New Jersey
    • ,
  • Philip Kantoff

      Affiliations

    • Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts

References 

  1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43
  2. Tannock IF, deWit R, Berry WR, Horti J, Pluzanska A, Chi KN. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502
  3. Petrylak DP, Tangen CM, Hussain MH, Lara PH, Jones JA, Taplin ME. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513
  4. Chirgwin JM, Mohammad KS, Guise TA. Tumor-bone cellular interactions in skeletal metastases. J Musculoskeletal Neuronal Interact. 2004;4:308
  5. Keller ET, Brown J. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem. 2004;91:718
  6. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350:1655
  7. Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med. 2006;12:17
  8. Mundy GR. Endothelin-1 and osteoblastic metastasis. Proc Natl Acad Sci U S A. 2003;100:10588
  9. Lynch CC, Hikosaka A, Acuff HB, Martin MD, Kawai N, Singh RK. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell. 2005;7:485
  10. Saad F. Bone-directed treatments for prostate cancer. Hematol Oncol Clin North Am. 2006;20:947
  11. Martin TJ. Paracrine regulation of osteoclast formation and activity: milestones in discovery. J Musculoskelet Neuronal Interact. 2004;4:243
  12. Berruti A, Piovesan A, Torta M, Raucci CA, Gorzegno G, Paccotti P. Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension. Br J Cancer. 1996;73:1581
  13. Vinholes J, Coleman R, Eastell R. Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment. Cancer Treat Rev. 1996;22:289
  14. Percival RC, Urwin GH, Harris S, Yates AJ, Williams JL, Beneton M. Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol. 1987;13:419
  15. Zhang J, Dai J, Qi Y, Lin DL, Smith P, Strayhorn C. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest. 2001;107:1235
  16. Carlin BI, Andriole GL. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer. 2000;88(suppl):2989
  17. Karsenty G. Bone formation and factors affecting this process. Matrix Biol. 2000;19:85
  18. Parfitt AM. The mechanism of coupling: a role for the vasculature. Bone. 2000;26:319
  19. Boyce BF, Hughes DE, Wright KR, Xing L, Dai A. Recent advances in bone biology provide insight into the pathogenesis of bone diseases. Lab Invest. 1999;79:83
  20. Kostenuik PJ. Revisiting the seed and soil theory of bone metastasis: new tools, same answer. J Musculoskelet Neuronal Interact. 2004;4:375
  21. Franceschi RT. The developmental control of osteoblast-specific gene expression: role of specific transcription factors and the extracellular matrix environment. Crit Rev Oral Biol Med. 1999;10:40
  22. Saad F, Clarke N, Colombel M. Natural history and treatment of bone complications in prostate cancer. Eur Urol. 2006;49:429
  23. Michaelson MD, Smith MR. Bisphosphonates for treatment and prevention of bone metastases. J Clin Oncol. 2005;23:8219
  24. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94:1458
  25. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96:879
  26. Ryan CW, Huo D, Demers LM, Beer TM, Lacerna LV. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol. 2006;176:972
  27. Michaelson MD, Kaufman DS, Lee H, McGovern FJ, Kantoff PW, Fallon MA. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol. 2007;25:1038
  28. Mason MD, Collaborators MP. Development of bone metastases from prostate cancer: first results of the MRC PR04 trial (ISCRTN 61384873). J Clin Oncol. 2004;22:4511
  29. Smith MR, Kabbinavar F, Saad F, Hussain A, Gittelman MC, Bilhartz DL. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol. 2005;23:2918
  30. Brubaker KD, Brown LG, Vessella RL, Corey E. Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment. BMC Cancer. 2006;6:15
  31. Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol. 2006;7:508
  32. Saad F, Higano CS, Sartor O, Colombel M, Murray R, Mason MD. The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel. Clin Genitourin Cancer. 2006;4:257
  33. Goblirsch M, Lynch C, Mathews W, Manivel JC, Mantyh PW, Clohisy DR, et al. Radiation treatment decreases bone cancer pain, osteolysis and tumor size. Radiat Res. 2004;161:228
  34. Porter AT, McEwan AJ, Powe JE, Reid R, McGowan DG, Lukka H. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 1993;25:805
  35. Sartor O, Reid RH, Hoskin PJ, Quick DP, Ell PJ, Coleman RE. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology. 2004;63:940
  36. Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet. 2001;357:336
  37. Tu SM, Kim J, Pagliaro LC, Vakar-Lopez F, Wong FC, Wen S. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol. 2005;23:7904
  38. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354:821
  39. Hamdy NA. Osteoprotegerin as a potential therapy for osteoporosis. Curr Rheumatol Rep. 2006;8:50
  40. Nemeth JA, Yousif R, Herzog M, Che M, Upadhyay J, Shekarriz B. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst. 2002;94:17
  41. Lara PN, Stadler WM, Longmate J, Quinn DI, Wexler J, VanLoan M. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. Clin Cancer Res. 2006;12:1556
  42. Shakespeare WC, Metcalf CA, Wang Y, Sundaramoorthi R, Keenan T, Weigele M. Novel bone-targeted Src tyrosine kinase inhibitor drug discovery. Curr Opin Drug Discov Devel. 2003;6:729
  43. Metcalf CA, vanSchravendijk MR, Dalgarno DC, Sawyer TK. Targeting protein kinases for bone disease: discovery and development of Src inhibitors. Curr Pharm Des. 2002;8:2049
  44. Shakespeare W, Yang M, Bohacek R, Cerasoli F, Stebbins K, Sundaramoorthi R. Structure-based design of an osteoclast-selective, nonpeptide src homology 2 inhibitor with in vivo antiresorptive activity. Proc Natl Acad Sci U S A. 2000;97:9373
  45. Pidgeon GP, Tang K, Cai YL, Piasentin E, Honn KV. Overexpression of platelet-type 12-lipoxygenase promotes tumor cell survival by enhancing alpha(v) beta(3) and alpha(v) beta(5) integrin expression. Cancer Res. 2003;63:4258
  46. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994;79:1157
  47. Teitelbaum SL. Osteoclasts and integrins. Ann N Y Acad Sci. 2006;1068:95
  48. Dresner-Pollak R, Rosenblatt M. Blockade of osteoclast-mediated bone resorption through occupancy of the integrin receptor: a potential approach to the therapy of osteoporosis. J Cell Biochem. 1994;56:323
  49. Beekman KW, Colevas AD, Cooney K, Dipaola R, Dunn RL, Gross M. Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design. Clin Genitourin Cancer. 2006;4:299
  50. Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med. 1995;1:944
  51. Yin JJ, Mohammad KS, Kakonen SM, Harris S, Wu-Wong JR, Wessale JL. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci U S A. 2003;100:10954
  52. Pirtskhalaishvili G, Nelson JB. Endothelium-derived factors as paracrine mediators of prostate cancer progression. Prostate. 2000;44:77
  53. Thakkar SG, Choueiri TK, Garcia JA. Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics. Curr Oncol Rep. 2006;8:108
  54. Nelson J, Bagnato A, Battistini B, Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer. 2003;3:110
  55. Gohji K, Kitazawa S, Tamada H, Katsuoka Y, Nakajima M. Expression of endothelin receptor a associated with prostate cancer progression. J Urol. 2001;165:1033
  56. Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol. 2003;21:679
  57. Vogelzang NJ, Nelson JB, Schulman CC, Dearnaley F, Saad F, Sleep JD. Meta-analysis of clinical trials of atrasentan 10 mg in metastatic hormone-refractory prostate cancer. J Clin Oncol. 2005;23:4563
  58. Lipton A, Sleep DJ, Hulting SM, Isaacson JD. Benefit of atrasentan in men with hormone refractory prostate cancer metastatic to bone. J Clin Oncol. 2004;22:4687
  59. Sleep DJ, Nelson JB, Petrylak DP, Isaacson JD, Carducci MA. Clinical benefit of atrasentan for men with metastatic hormone-refractory prostate cancer metastatic to bone. J Clin Oncol. 2006;24:4630
  60. Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst. 2005;97:59
  61. Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol. 2005;23:4925
  62. Pectasides D, Nikolaou M, Farmakis D, Kanakis I, Gaaglia A, Kountourakis P. Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid. Anticancer Res. 2005;25:1457
  63. Carducci M, Nelson JB, Saad F, Vogelznang NJ, Zonnenberg BA, Daliani DD. Effects of atrasentan on disease progression and biological markers in men with metastatic hormone-refractory prostate cancer: phase 3 study. J Clin Oncol. 2004;22:4508
  64. Moffat BA, Chenevert TL, Lawrence TS, Meyer CR, Johnson TD, Dong Q. Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A. 2005;102:5524
  65. Hamstra DA, Chenevert TL, Moffat BA, Johnson TD, Meyer CR, Mukherji SK. Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A. 2005;102:16759
  66. Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol. 2003;21:4277
  67. Dearnaley DP, Sydes MR, Mason MD, Stott M, Powell CS, Robinson AC. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst. 2003;95:1300
  68. Quinn JE, Brown LG, Zhang J, Keller ET, Vessella RL, Corey E. Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms. Prostate Cancer Prostatic Dis. 2005;8:253
  69. Hall CL, Keller ET. The role of Wnts in bone metastases. Cancer Metastasis Rev. 2006;25:551
  70. Haudenschild DR, Palmer SM, Moseley TA, You Z, Reddi AH. Bone morphogenetic protein (BMP)-6 signaling and BMP antagonist noggin in prostate cancer. Cancer Res. 2004;64:8276
  71. Dai J, Keller J, Zhang J, Lu Y, Yao Z, Keller ET. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res. 2005;65:8274

 Supported by National Institutes of Health Grant T32CA009357 (DAB).

PII: S0022-5347(07)01094-4

doi: 10.1016/j.juro.2007.04.035

The Journal of Urology
Volume 178, Issue 3, Supplement , Pages S42-S48 , September 2007

Article Tools

* Image Usage & Resolution